Experienced in Graft Versus Host Disease (GvHD)

Dr. Thomas Prebet

Hematology | Oncology
Yale University
20 York St, 
New Haven, CT 
Offers Telehealth
Experienced in Graft Versus Host Disease (GvHD)
Yale University
20 York St, 
New Haven, CT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Thomas Prebet is a Hematologist and an Oncologist in New Haven, Connecticut. Dr. Prebet is rated as an Experienced provider by MediFind in the treatment of Graft Versus Host Disease (GvHD). His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

His clinical research consists of co-authoring 135 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles in the study of Graft Versus Host Disease (GvHD).

Specialties
Hematology
Oncology
Licenses
Internal Medicine in CT
Hospital Affiliations
Yale-New Haven Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 2 Less Insurance Carriers -

Locations

YALE UNIVERSITY
20 York St, New Haven, CT 06510

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Drug, Procedure
Study Drugs: Cytarabine, Daunorubicin, Uproleselan
Study Phase: Phase 2/Phase 3
The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. A Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. A Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: September 10, 2025
Intervention Type: Procedure, Drug
Study Drug: Olaparib
Study Phase: Phase 2
A Phase 1b/2 Study of Pinometostat in Combination With Standard Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia With MLL Rearrangement
A Phase 1b/2 Study of Pinometostat in Combination With Standard Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia With MLL Rearrangement
Enrollment Status: Terminated
Publish Date: June 18, 2025
Intervention Type: Drug
Study Drugs: Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Pinometostat
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study of SL-401 as Consolidation Therapy for Adult Patients With Adverse Risk Acute Myeloid Leukemia in First CR, and/or Evidence of Minimal Residual Disease (MRD) in First CR
A Phase 1/2 Study of SL-401 as Consolidation Therapy for Adult Patients With Adverse Risk Acute Myeloid Leukemia in First CR, and/or Evidence of Minimal Residual Disease (MRD) in First CR
Enrollment Status: Terminated
Publish Date: October 17, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase I/II Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Efficacy of ONO-7475 in Patients With Acute Leukemias or Myelodysplastic Syndromes
A Phase I/II Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Efficacy of ONO-7475 in Patients With Acute Leukemias or Myelodysplastic Syndromes
Enrollment Status: Terminated
Publish Date: July 15, 2024
Intervention Type: Drug
Study Drugs: ONO-7475, Venetoclax
Study Phase: Phase 1/Phase 2
A Phase I-II Study of Triciribine Phosphate Monohydrate (PTX-200) Plus Cytarabine in Refractory or Relapsed Acute Leukemia
A Phase I-II Study of Triciribine Phosphate Monohydrate (PTX-200) Plus Cytarabine in Refractory or Relapsed Acute Leukemia
Enrollment Status: Completed
Publish Date: April 05, 2024
Intervention Type: Drug
Study Drugs: PTX-200, Cytarabine
Study Phase: Phase 1/Phase 2
Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)
Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)
Enrollment Status: Completed
Publish Date: August 18, 2022
Intervention Type: Drug
Study Drug: Nilotinib
Study Phase: Phase 2
A Phase I-II Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia
A Phase I-II Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: April 08, 2022
Intervention Type: Drug
Study Drug: Nintedanib
Study Phase: Phase 2
A Phase I-II Study of a Liposomal Formulation of Cytarabine and Daunorubicin (CPX-351) in Patients Treated for Higher-risk Myelodysplastic Syndromes Experiencing Hypomethylating Agent Failure.
A Phase I-II Study of a Liposomal Formulation of Cytarabine and Daunorubicin (CPX-351) in Patients Treated for Higher-risk Myelodysplastic Syndromes Experiencing Hypomethylating Agent Failure.
Enrollment Status: Withdrawn
Publish Date: January 24, 2022
Intervention Type: Drug
Study Drug: CPX-351
Study Phase: Phase 1/Phase 2
A Phase II of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS
A Phase II of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS
Enrollment Status: Withdrawn
Publish Date: January 20, 2022
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

135 Total Publications

Evaluation of the pharmacokinetics of enasidenib in patients with hepatic impairment.
Evaluation of the pharmacokinetics of enasidenib in patients with hepatic impairment.
Journal: Cancer chemotherapy and pharmacology
Published: May 05, 2025
Similar Doctors
Elite in Graft Versus Host Disease (GvHD)
Dr. Ran Reshef
Hematology | Hematology Oncology
Elite in Graft Versus Host Disease (GvHD)
Dr. Ran Reshef
Hematology | Hematology Oncology

Trustees Of Columbia University In The City Of New York

161 Fort Washington Ave, 
New York, NY 
 (61.5 miles away)
212-305-3870
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ran Reshef is a Hematologist and a Hematologist Oncology provider in New York, New York. Dr. Reshef is rated as a Distinguished provider by MediFind in the treatment of Graft Versus Host Disease (GvHD). His top areas of expertise are Graft Versus Host Disease (GvHD), Multiple Myeloma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Mitchell Cairo
Distinguished in Graft Versus Host Disease (GvHD)
Dr. Mitchell Cairo
Hematology | Oncology
Distinguished in Graft Versus Host Disease (GvHD)
Dr. Mitchell Cairo
Hematology | Oncology

Bradhurst Avenue Specialty Office

19 Bradhurst Avenue, 
Hawthorne, NY 
 (47.4 miles away)
914-614-4270
Languages Spoken:
English
See accepted insurances

Mitchell Cairo is a Hematologist and an Oncologist in Hawthorne, New York. Dr. Cairo is rated as an Elite provider by MediFind in the treatment of Graft Versus Host Disease (GvHD). His top areas of expertise are Burkitt Lymphoma, B-Cell Lymphoma, Primary Mediastinal B-Cell Lymphoma (PMBCL), Non-Hodgkin Lymphoma, and Bone Marrow Transplant.

Advanced in Graft Versus Host Disease (GvHD)
Dr. Markus Y. Mapara
Oncology | Hematology | Hematology Oncology
Advanced in Graft Versus Host Disease (GvHD)
Dr. Markus Y. Mapara
Oncology | Hematology | Hematology Oncology

Trustees Of Columbia University In The City Of New York

161 Fort Washington Ave, 
New York, NY 
 (61.5 miles away)
212-305-3870
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Markus Mapara is an Oncologist and a Hematologist in New York, New York. Dr. Mapara is rated as a Distinguished provider by MediFind in the treatment of Graft Versus Host Disease (GvHD). His top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Bone Marrow Transplant, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Prebet's expertise for a condition
ConditionClose
View All 13 Advanced Conditions
View All 26 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile